Clinical Strategies to Optimize NSCLC Immuno-oncology in the Second-line Setting
A CME-certified Lunch Symposium in conjunction with the IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  Chicago Marriott Downtown Magnificent Mile
Chicago Ballroom, 5th Floor
ChicagoIL Friday
Sep 23, 2016 12:00 PM


Presentation Slides

Click here to view the presentation slides from this CME-certified symposium. (coming soon)

Download (PDF) Click here to view the presentation slides from this CME-certified symposium.

Program Description

Immuno-oncology is revolutionizing the treatment landscape for lung cancer. As new agents emerge, clinicians are challenged to incorporate new molecular information that can guide treatment selections. Clinical Strategies to Optimize NSCLC Immuno-oncology in the Second-line Setting will facilitate the seamless transition of new immunotherapeutic agents into clinical practice, with specific exploration of the role of the immune system, the nuances of biomarker testing, revised clinical guidelines, and emerging data.

Agenda

Registration: 12:00-12:30 PM
CME program: 12:30 – 1:30 PM

Welcome
Biological Foundations of Immuno-oncology
Case-based Discussions
         Practical Immuno-oncology
Panel Discussion
         The Next Chapter in Immuno-oncology
Q&A Session

Target Audience

This activity is intended for academic and community oncologists, pathologists, advanced practice nurses, and other healthcare professionals involved in the management of patients with NSCLC.


Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:
  • Improve awareness of the mechanisms of action of immunotherapeutic approaches for the treatment of NSCLC
  • Integrate strategies to optimize PD-L1 testing
  • Compare and contrast the efficacy of current and emerging immunotherapeutic agents in treating squamous and non-squamous NSCLC
  • Collaborate with patients and treatment teams to manage adverse events unique to immuno-oncology

Program Faculty

Balazs Halmos, MD
Director, Thoracic Oncology and Clinical Cancer Genomics
Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, NY

Una Hopkins, DNP
Administrative Director Cancer Program 
White Plains Hospital 
White Plains, NY

 

 

Ignacio I. Wistuba, MD
Professor and Chair
Department of Translational Molecular Pathology
The University of Texas MD Anderson Cancer Center
Houston, TX


Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.


FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided after submission of a completed evaluation form.

There is no fee associated with this program.

SPECIAL SERVICES

Event staff will be glad to assist you with any specials needs.  Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.

PROVIDED BY


Jointly provided by the Potomac Center for Medical Education and Rockpointe Oncology

     
     

     


SUPPORTED BY


Supported by educational grants from Bristol-Myers Squibb and Merck & Co., Inc.

Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.

Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.



Registration

  VenueCityStateDate
View Agenda  Chicago Marriott Downtown Magnificent Mile
Chicago Ballroom, 5th Floor
ChicagoIL Friday
Sep 23, 2016 12:00 PM